ONCAlert | Upfront Therapy for mRCC
Breast Cancer Case Studies

Case Studies: HR+ Metastatic Breast Cancer

Breast cancer expert Sara M. Tolaney, MD, MPH, discusses the rationale for treating a 58-year-old woman with metastatic ER-positive/HER2-negative with a CDK4/6 inhibitor and endocrine therapy following progression on an aromatase inhibitor.

HR+ Metastatic Breast Cancer

Case:  A 58-Year-Old Woman With Metastatic ER+ Ductal Carcinoma

  • 58-year-old woman with estrogen-receptor-positive (ER+), progesterone-receptor-negative (PR-), HER2-negative (HER2-) invasive ductal carcinoma (IDC) of L breast; she completed adjuvant anastrozole for 5 years
  • Now, 13 months later, she presents with 4 small (<1.0 cm) asymptomatic lesions in the left lung and mediastinal and hilar lymphadenopathy.
  • Mediastinoscopy was performed and confirmed ER+ PR- Her2- carcinoma
  • ECOG PS: 0
  • The patient was started on abemaciclib + fulvestrant
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.